Comparing comparators: a look at control arms in kidney cancer studies over the years

por Bracarda, S, Porta, C, Sisani, M, Marrocolo, F, Paglino, C, Hamzaj, A, D Buono, S, Sternberg, C N
Publicado 2015

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.

por Fosså, S. D., Sternberg, C., Scher, H. I., Theodore, C. H., Mead, B., Dearnaley, D., Roberts, J. T., Skovlund, E.
Publicado 1996

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)

por Fernandes, G.S., Sternberg, C., Lopes, G., Chammas, R., Gifoni, M.A.C., Gil, R.A., Araujo, D.V.
Publicado 2018

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

por Tombal, B., Sternberg, C.N., Hussain, M., Ganguli, A., Li, Y., Sandin, R., Bhadauria, H., Oh, M., Saad, F.
Publicado 2022

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice

por Grivas, P., Grande, E., Davis, I.D., Moon, H.H., Grimm, M.-O., Gupta, S., Barthélémy, P., Thibault, C., Guenther, S., Hanson, S., Sternberg, C.N.
Publicado 2023

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.

por Sternberg, C. N., ten Bokkel Huinink, W. W., Smyth, J. F., Bruntsch, V., Dirix, L. Y., Pavlidis, N. A., Franklin, H., Wanders, S., Le Bail, N., Kaye, S. B.
Publicado 1994

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

por Zurita, A J, Gagnon, R C, Liu, Y, Tran, H T, Figlin, R A, Hutson, T E, D'Amelio Jr, A M, Sternberg, C N, Pandite, L N, Heymach, J V
Publicado 2017

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expressi...

por Bamias, A., Merseburger, A.S., Loriot, Y., James, N., Choy, E., Castellano, D., Lopez-Rios, F., Calabrò, F., Kramer, M., de Velasco, G., Zakopoulou, R., Tzannis, K., Sternberg, C.N.
Publicado 2021

First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

por Aeppli, S., Schmaus, M., Eisen, T., Escudier, B., Grünwald, V., Larkin, J., McDermott, D., Oldenburg, J., Porta, C., Rini, B.I., Schmidinger, M., Sternberg, C.N., Rothermundt, C., Putora, P.M.
Publicado 2021

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

por Bryce, A H, Alumkal, J J, Armstrong, A, Higano, C S, Iversen, P, Sternberg, C N, Rathkopf, D, Loriot, Y, de Bono, J, Tombal, B, Abhyankar, S, Lin, P, Krivoshik, A, Phung, D, Beer, T M
Publicado 2017

Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer

por de Almeida, V.H., de Melo, A.C., Meira, D.D., Pires, A.C., Nogueira-Rodrigues, A., Pimenta-Inada, H.K., Alves, F.G., Moralez, G., Thiago, L.S., Ferreira, C.G., Sternberg, C.
Publicado 2017

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma

por Xu, C-F, Johnson, T, Garcia-Donas, J, Choueiri, T K, Sternberg, C N, Davis, I D, Bing, N, Deen, K C, Xue, Z, McCann, L, Esteban, E, Whittaker, J C, Spraggs, C F, Rodríguez-Antona, C, Pandite, L N, Motzer, R J
Publicado 2015

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

por Fornarini, G., Rebuzzi, S.E., Banna, G.L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., Sternberg, C.N.
Publicado 2021

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus ab...

por de Wit, R., Wülfing, C., Castellano, D., Kramer, G., Eymard, J.-C., Sternberg, C.N., Fizazi, K., Tombal, B., Bamias, A., Carles, J., Iacovelli, R., Melichar, B., Sverrisdóttir, Á., Theodore, C., Feyerabend, S., Helissey, C., Foster, M.C., Ozatilgan, A., Geffriaud-Ricouard, C., de Bono, J.
Publicado 2021

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

por Fradet, Y, Bellmunt, J, Vaughn, D J, Lee, J L, Fong, L, Vogelzang, N J, Climent, M A, Petrylak, D P, Choueiri, T K, Necchi, A, Gerritsen, W, Gurney, H, Quinn, D I, Culine, S, Sternberg, C N, Nam, K, Frenkl, T L, Perini, R F, de Wit, R, Bajorin, D F
Publicado 2019

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

por Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., Soule, H. R., Akaza, H., Beer, T. M., Beltran, H., Chinnaiyan, A. M., Daugaard, G., Davis, I. D., De Santis, M., Drake, C. G., Eeles, R. A., Fanti, S., Gleave, M. E., Heidenreich, A., Hussain, M., James, N. D., Lecouvet, F. E., Logothetis, C. J., Mastris, K., Nilsson, S., Oh, W. K., Olmos, D., Padhani, A. R., Parker, C., Rubin, M. A., Schalken, J. A., Scher, H. I., Sella, A., Shore, N. D., Small, E. J., Sternberg, C. N., Suzuki, H., Sweeney, C. J., Tannock, I. F., Tombal, B.
Publicado 2015